The Latest: FDA panel endorses potential 1st US gene therapy

• Share on Facebook
• Share on Bluesky
• Share on X
• Copy Link

The therapy could be the first of a wave of treatments custom-made to target a patient’s cancer. Called CAR-T, it involves removing immune cells from a patients’ blood, reprogramming them to create an army of cells to recognize and destroy cancer and injecting them back into the patient.

Two & Out

PETERS: Did council take middle ground or refuse to make a decision on Upper Sahali proposal?

2h ago

Looped In

LOOPED IN WITH NIKKI OMEN: September 3, 2026

Sep 03, 2026

1000 Ways to Heal

1000 WAYS TO HEAL: We were never meant to carry it alone

Sep 03, 2026

The FDA is not required to follow the panel’s recommendation but often does.

10:30 a.m.

Cancer experts who advise government regulators are reviewing what could be the first gene therapy approved in the U.S.

The Food and Drug Administration panel is holding a hearing Wednesday to discuss the treatment developed by the University of Pennsylvania and Novartis Corp. The drugmaker is seeking approval to use the one-time treatment for children and young adults with advanced leukemia.

The therapy could be the first of a wave of cancer treatments custom-made to target a patient’s cancer. Called CAR-T, it involves removing immune cells from a patients’ blood, reprogramming them to create an army of attack cells and putting them back into the patient.

The panel is reviewing the safety, effectiveness and production of the treatment. It will vote on whether to recommend FDA approval.

The Associated Press